In this study, the Orbis PAXMAN® scalpcooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.
62 citations
,
February 2011 in “Expert review of dermatology”
This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalpcooling is the most effective prevention method in most cases, though some questions remain.
21 citations
,
January 2015 in “Oncology Research and Treatment”
This study found that sensor-controlled scalpcooling was effective in preventing hair loss during chemotherapy, particularly in premenopausal patients and those without systemic comorbidities or additional medications.
Topical dutasteride is more effective than finasteride for hair loss but lacks FDA approval and research, leading to less use. Users report varying effectiveness and side effects, with some preferring oral treatments.